spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ARIAD Pharmaceuticals 

 HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Nov 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 24 Sep 2018
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Apr 2018
Clarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Jun 2017
Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 18 Dec 2015
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2014
ARIAD Announces Three Key Appointments to Its Global Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2014
Cohera Medical, Inc.(R) Appoints Richard W. Pascoe to its Board of Directors
Devices Surgery Personnel
 HSMN NewsFeed - 2 Apr 2014
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jan 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Jan 2014
KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Nov 2013
ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jul 2013
Warp Drive Bio Appoints Co-Founder Gregory Verdine, Ph.D., to Chief Executive Officer; Expands Team with Two Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2013
Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2012
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
Diagnostics Venture Capital
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 5 May 2010
Merck Acquires Development and Commercialization Rights to Investigational mTOR Inhibitor Ridaforolimus from ARIAD Pharmaceuticals, Inc.
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 5 Apr 2010
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2009
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2009
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2008
ARIAD Announces Court Rulings Regarding NF-(kappa)B Patent Lawsuit with Amgen
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Sep 2008
ARIAD Announces Merger with ARIAD Gene Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Aug 2008
Somaxon Pharmaceuticals Appoints Richard W. Pascoe as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2008
ARIAD Appoints Former Bristol-Myers Squibb Executive to Lead Corporate Legal and Compliance Functions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2008
ARIAD Appoints Richard W. Pascoe as Chief Operating Officer and Expands Role of Timothy P. Clackson, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2008
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Nov 2007
ARIAD Expands Leadership Team with Three New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2007
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 2 Oct 2007
ARIAD Names Vice President, Clinical Operations to Further Enhance Global Clinical Development Efforts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ARIAD Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Oral Deforolimus
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Feb 2007
ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Nov 2006
ARIAD Presents Expanded Efficacy Data On AP23573, Novel mTOR Inhibitor, In Phase 2 Advanced Sarcoma Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2006
ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Oct 2006
Bellicum Pharmaceuticals Announces Commercial Licensing of ARIAD's ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Sep 2006
ARIAD Announces Update Regarding NF-(kappa)B Patent Lawsuit with Amgen
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 May 2006
Jury Issues Verdict in Ariad v. Lilly Patent Infringement Suit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 May 2006
Jury Rules in Favor of ARIAD and Co-Plaintiffs in Lilly NF-(kappa)B Patent Infringement Lawsuit
Biopharmaceuticals Litigation
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
ARIAD Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.